強
強気
強気 · 25%HKPD
$1.53
シナリオ価格
$1.450
+0.096 (+6.62%)終値時点
Loading chart…
- 高値
- 1.600
- 始値
- 1.420
- 出来高加重平均価格
- 1.47
- 出来高
- 48.81K
- 時価総額
- —
- 安値
- 1.360
- 売買代金
- 71.76K
- EV/EBITDA（TTM）
- 0.00
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
AI分析 of Cellyan Biotechnology Co Ltd (HKPD)
売りGiven the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
バリュエーション指標
Cellyan Biotechnology Co Ltd（HKPD）の現在の予想PERは0.00で、5年平均は0.00です。
Alphio AI による HKPD の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
7.007-17NASDAQ.COMCellyan Biotechnology Receives Nasdaq Compliance Extension
8.507-16seekingalphaCellyan Biotechnology Secures Nasdaq Compliance Extension
- 8.501-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
7.001-16GlobenewswireCellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
- 9.012-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
HKPD のよくある質問 — Alphio AI が回答
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services. It operates in the Healthcare sector.
Given the current price of 1.45, the RSI at 25.446 indicates that the stock is oversold, but the significant year-to-date decline of 91.01% and negative earnings trends suggest that this is not a good buy right now. The main risk is the compliance warning from Nasdaq, which could further impact investor confidence and stock performance.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。